Contract manufacturers BioCina and Genezen name new CEOs
A pair of CDMOs are bringing in new CEOs.
Taking the helm at BioCina is Mark Womack. According to his LinkedIn profile, Womack has been in leadership positions at several contract manufacturers. His career spans more than 30 years, including roles such as CEO of the contract manufacturer KBI Biopharma and Selexis SA. Before that, he was CEO of Stelis Biopharma and chief business officer of Seattle-based manufacturer AGC Biologics.
Former BioCina CEO Ian Wisenberg will join the board of directors as executive chairman.
“I’m tremendously excited to lead the highly talented and deeply committed BioCina team and to build on all of the success they’ve achieved to date. Leveraging BioCina’s core strengths, we will become a preeminent Global Biologics CDMO through industry-leading quality, a client-centric approach and on-time delivery of client programs,” Womack announced in a release.
In 2021, BioCina finalized its takeover of a 60,000-square-foot former Pfizer site in Australia to boost its mRNA production.
The Indiana-based cell and gene therapy CDMO Genezen has also made a change at the top, announcing Steven Favaloro as its new president and CEO.
According to his LinkedIn page, Favaloro previously served as the CFO of several companies including Arbor Biotechnologies, Arranta Bio, and Brammer Bio. Favaloro also has a decade of experience in the viral vector manufacturing space.
“Genezen is at an exciting point in its journey following the recent opening of a world-class GMP facility close to Indianapolis. I am excited to lead a talented group of colleagues at Genezen and to partner with customers in delivering the next generation of novel treatments,” Favaloro said in a release.
Favaloro joins Genezen after the company finished a new 75,000-square-foot manufacturing facility in September of last year.